Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 224

1.

Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma.

Petrova E, Zielinski V, Bolm L, Schreiber C, Knief J, Thorns C, Bronsert P, Timme-Bronsert S, Bausch D, Perner S, Keck T, Wellner U.

Virchows Arch. 2019 Nov 30. doi: 10.1007/s00428-019-02719-1. [Epub ahead of print]

PMID:
31786688
2.

ATM activity in T cells is critical for immune surveillance of lymphoma in vivo.

Riabinska A, Lehrmann D, Jachimowicz RD, Knittel G, Fritz C, Schmitt A, Geyer A, Heneweer C, Wittersheim M, Frenzel LP, Torgovnick A, Wiederstein JL, Wunderlich CM, Ortmann M, Paillard A, Wößmann W, Borkhardt A, Burdach S, Hansmann ML, Rosenwald A, Perner S, Mall G, Klapper W, Merseburg A, Krüger M, Grüll H, Persigehl T, Wunderlich FT, Peifer M, Utermöhlen O, Büttner R, Beleggia F, Reinhardt HC.

Leukemia. 2019 Nov 5. doi: 10.1038/s41375-019-0618-2. [Epub ahead of print]

PMID:
31690822
3.

[Report of the Head and Neck Pathology Working Group : 103rd Annual Meeting of the German Society for Pathology in Frankfurt am Main on 13.06.2019].

Perner S.

Pathologe. 2019 Oct 28. doi: 10.1007/s00292-019-00646-1. [Epub ahead of print] German. No abstract available.

PMID:
31659395
4.

[Status of the availability and use of next generation sequencing (NGS) in bladder cancer-a questionnaire within the uropathology working group].

Ortiz-Brüchle N, Muders M, Toma M, Esposito I, Hartmann A, Stöhr R, Reis H, Wild P, Köllermann J, Bremmer F, Leichsenring J, Stenzinger A, Merkelbach-Bruse S, Kirfel S, Perner S, Hartmann N, Roth W, Jung A, Kirchner T, Schwamborn K, Pfarr N, Dahl E, Knüchel R, Gaisa NT.

Urologe A. 2019 Sep 20. doi: 10.1007/s00120-019-01046-2. [Epub ahead of print] Review. German.

PMID:
31541269
5.

Comprehensive in situ analysis of ALDH1 and SOX2 reveals increased expression of stem cell markers in high-grade serous carcinomas compared to low-grade serous carcinomas and atypical proliferative serous tumors.

Fischer AK, Pham DL, Bösmüller H, Lengerke C, Wagner P, Bachmann C, Beschorner C, Perner S, Kommoss S, Fend F, Staebler A.

Virchows Arch. 2019 Oct;475(4):479-488. doi: 10.1007/s00428-019-02647-0. Epub 2019 Aug 27.

PMID:
31451895
6.

A randomized trial (RAREST-01) comparing Mepitel® Film and standard care for prevention of radiation dermatitis in patients irradiated for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN).

Rades D, Narvaez CA, Splettstößer L, Dömer C, Setter C, Idel C, Ribbat-Idel J, Perner S, Bartscht T, Olbrich D, Schild SE, Carl J.

Radiother Oncol. 2019 Oct;139:79-82. doi: 10.1016/j.radonc.2019.07.023. Epub 2019 Aug 17.

PMID:
31431372
7.

Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients.

Kuempers C, van der Linde LIS, Reischl M, Vogel W, Stellmacher F, Reck M, Heigener D, Rabe KF, Kirfel J, Perner S, Welker L.

Virchows Arch. 2019 Aug 7. doi: 10.1007/s00428-019-02632-7. [Epub ahead of print]

PMID:
31392467
8.

[Status quo 5 years after the introduction of the new ISUP 2014/WHO 2016 prostate cancer grade groups].

Hupe MC, Offermann A, Sailer V, Merseburger AS, Perner S.

Aktuelle Urol. 2019 Dec;50(6):619-624. doi: 10.1055/a-0918-9473. Epub 2019 Aug 7. German.

PMID:
31390661
9.

Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.

Becker F, Joerg V, Hupe MC, Roth D, Krupar R, Lubczyk V, Kuefer R, Sailer V, Duensing S, Kirfel J, Merseburger AS, Brägelmann J, Perner S, Offermann A.

Int J Cancer. 2020 Jan 15;146(2):577-588. doi: 10.1002/ijc.32551. Epub 2019 Jul 19.

PMID:
31271443
10.

TRIM24 as an independent prognostic biomarker for prostate cancer.

Offermann A, Roth D, Hupe MC, Hohensteiner S, Becker F, Joerg V, Carlsson J, Kuempers C, Ribbat-Idel J, Tharun L, Sailer V, Kirfel J, Svensson M, Andren O, Lubczyk V, Kuefer R, Merseburger AS, Perner S.

Urol Oncol. 2019 Sep;37(9):576.e1-576.e10. doi: 10.1016/j.urolonc.2019.05.006. Epub 2019 Jun 7.

PMID:
31178279
11.

KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells.

Metzger E, Wang S, Urban S, Willmann D, Schmidt A, Offermann A, Allen A, Sum M, Obier N, Cottard F, Ulferts S, Preca BT, Hermann B, Maurer J, Greschik H, Hornung V, Einsle O, Perner S, Imhof A, Jung M, Schüle R.

Nat Struct Mol Biol. 2019 May;26(5):361-371. doi: 10.1038/s41594-019-0219-9. Epub 2019 May 6.

PMID:
31061526
12.

[Molecular tumor board in uro-oncology-from a pathologist's view].

Gaisa NT, Kristiansen G, Perner S.

Urologe A. 2019 Jul;58(7):747-751. doi: 10.1007/s00120-019-0934-1. Review. German.

PMID:
31049636
13.

Intralesional interleukin-2: A novel option to maximize response to systemic immune checkpoint therapy in loco-regional metastatic melanoma.

Langan EA, Kümpers C, Graetz V, Perner S, Zillikens D, Terheyden P.

Dermatol Ther. 2019 May;32(3):e12901. doi: 10.1111/dth.12901. Epub 2019 Apr 29.

PMID:
30974014
14.

The new ISUP 2014/WHO 2016 prostate cancer grade group system: first résumé 5 years after introduction and systemic review of the literature.

Offermann A, Hupe MC, Sailer V, Merseburger AS, Perner S.

World J Urol. 2019 Apr 2. doi: 10.1007/s00345-019-02744-4. [Epub ahead of print] Review.

PMID:
30941561
15.

Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma.

Kümpers C, Jokic M, Haase O, Offermann A, Vogel W, Grätz V, Langan EA, Perner S, Terheyden P.

Front Med (Lausanne). 2019 Mar 13;6:27. doi: 10.3389/fmed.2019.00027. eCollection 2019.

16.

Investigation of Reduced ELISA Recovery of Almond and Hazelnut Traces from Roasted Nut Samples by SDS-PAGE and Mass Spectrometry.

Perner SP, Heupel L, Zimmermann L, Peters Y, Vongehr KU, El-Bedewy H, Siebeneicher S, Weiß T, Hektor T, Lindemann B, Loos-Theisen S, Schneider K.

J AOAC Int. 2019 Sep 1;102(5):1271-1279. doi: 10.5740/jaoacint.19-0055. Epub 2019 Mar 19.

PMID:
30890205
17.

Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.

Hupe MC, Philippi C, Roth D, Kümpers C, Ribbat-Idel J, Becker F, Joerg V, Duensing S, Lubczyk VH, Kirfel J, Sailer V, Kuefer R, Merseburger AS, Perner S, Offermann A.

Front Oncol. 2018 Dec 20;8:623. doi: 10.3389/fonc.2018.00623. eCollection 2018.

18.

A mechanistic classification of clinical phenotypes in neuroblastoma.

Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, Bartenhagen C, Walter E, Gecht J, Kerschke L, Volland R, Menon R, Heuckmann JM, Gartlgruber M, Hartlieb S, Henrich KO, Okonechnikov K, Altmüller J, Nürnberg P, Lefever S, de Wilde B, Sand F, Ikram F, Rosswog C, Fischer J, Theissen J, Hertwig F, Singhi AD, Simon T, Vogel W, Perner S, Krug B, Schmidt M, Rahmann S, Achter V, Lang U, Vokuhl C, Ortmann M, Büttner R, Eggert A, Speleman F, O'Sullivan RJ, Thomas RK, Berthold F, Vandesompele J, Schramm A, Westermann F, Schulte JH, Peifer M, Fischer M.

Science. 2018 Dec 7;362(6419):1165-1170. doi: 10.1126/science.aat6768.

PMID:
30523111
19.

Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer.

Kesch C, Radtke JP, Wintsche A, Wiesenfarth M, Luttje M, Gasch C, Dieffenbacher S, Pecqueux C, Teber D, Hatiboglu G, Nyarangi-Dix J, Simpfendörfer T, Schönberg G, Dimitrakopoulou-Strauss A, Freitag M, Duensing A, Grüllich C, Jäger D, Götz M, Grabe N, Schweiger MR, Pahernik S, Perner S, Herpel E, Roth W, Wieczorek K, Maier-Hein K, Debus J, Haberkorn U, Giesel F, Galle J, Hadaschik B, Schlemmer HP, Hohenfellner M, Bonekamp D, Sültmann H, Duensing S.

Sci Rep. 2018 Nov 12;8(1):16708. doi: 10.1038/s41598-018-35058-3.

20.

The Cdkn1aSUPER Mouse as a Tool to Study p53-Mediated Tumor Suppression.

Torgovnick A, Heger JM, Liaki V, Isensee J, Schmitt A, Knittel G, Riabinska A, Beleggia F, Laurien L, Leeser U, Jüngst C, Siedek F, Vogel W, Klümper N, Nolte H, Wittersheim M, Tharun L, Castiglione R, Krüger M, Schauss A, Perner S, Pasparakis M, Büttner R, Persigehl T, Hucho T, Herter-Sprie GS, Schumacher B, Reinhardt HC.

Cell Rep. 2018 Oct 23;25(4):1027-1039.e6. doi: 10.1016/j.celrep.2018.09.079.

21.

Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence.

Pasternack H, Fassunke J, Plum PS, Chon SH, Hescheler DA, Gassa A, Merkelbach-Bruse S, Bruns CJ, Perner S, Hallek M, Büttner R, Bollschweiler E, Hölscher AH, Quaas A, Zander T, Weiss J, Alakus H.

Sci Rep. 2018 Oct 8;8(1):14941. doi: 10.1038/s41598-018-33027-4.

22.

Correction to: DNA methylation-based reclassification of olfactory neuroblastoma.

Capper D, Engel NW, Stichel D, Lechner M, Glöss S, Schmid S, Kölsche C, Schrimpf D, Niesen J, Wefers AK, Jones DTW, Sill M, Weigert O, Ligon KL, Olar A, Koch A, Forster M, Moran S, Tirado OM, Sáinz-Jaspeado M, Mora J, Esteller M, Alonso J, Del Muro XG, Paulus W, Felsberg J, Reifenberger G, Glatzel M, Frank S, Monoranu CM, Lund VJ, von Deimling A, Pfister S, Buslei R, Ribbat-Idel J, Perner S, Gudziol V, Meinhardt M, Schüller U.

Acta Neuropathol. 2018 Sep;136(3):505. doi: 10.1007/s00401-018-1887-y.

PMID:
30094618
23.

Correction: AIM2 Drives Joint Inflammation in a Self-DNA Triggered Model of Chronic Polyarthritis.

Jakobs C, Perner S, Hornung V.

PLoS One. 2018 Aug 9;13(8):e0202364. doi: 10.1371/journal.pone.0202364. eCollection 2018.

24.

Fountain of youth for squamous cell carcinomas? On the epigenetic age of non-small cell lung cancer and corresponding tumor-free lung tissues.

Marwitz S, Heinbockel L, Scheufele S, Kugler C, Reck M, Rabe KF, Perner S, Goldmann T, Ammerpohl O.

Int J Cancer. 2018 Dec 15;143(12):3061-3070. doi: 10.1002/ijc.31641. Epub 2018 Oct 16.

25.

The BET-inhibitor PFI-1 diminishes AR/AR-V7 signaling in prostate cancer cells.

Hupe MC, Hoda MR, Zengerling F, Perner S, Merseburger AS, Cronauer MV.

World J Urol. 2019 Feb;37(2):343-349. doi: 10.1007/s00345-018-2382-8. Epub 2018 Jun 22.

PMID:
29934670
26.

Genomic features of renal cell carcinoma with venous tumor thrombus.

Warsow G, Hübschmann D, Kleinheinz K, Nientiedt C, Heller M, Van Coile L, Tolstov Y, Trennheuser L, Wieczorek K, Pecqueux C, Gasch C, Kuru T, Nyarangi-Dix J, Hatiboglu G, Teber D, Perner S, Stenzinger A, Roth W, Hadaschik B, Pahernik S, Jäger D, Grüllich C, Duensing A, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Duensing S.

Sci Rep. 2018 May 10;8(1):7477. doi: 10.1038/s41598-018-25544-z.

27.

DNA methylation-based reclassification of olfactory neuroblastoma.

Capper D, Engel NW, Stichel D, Lechner M, Glöss S, Schmid S, Koelsche C, Schrimpf D, Niesen J, Wefers AK, Jones DTW, Sill M, Weigert O, Ligon KL, Olar A, Koch A, Forster M, Moran S, Tirado OM, Sáinz-Jaspeado M, Mora J, Esteller M, Alonso J, Del Muro XG, Paulus W, Felsberg J, Reifenberger G, Glatzel M, Frank S, Monoranu CM, Lund VJ, von Deimling A, Pfister S, Buslei R, Ribbat-Idel J, Perner S, Gudziol V, Meinhardt M, Schüller U.

Acta Neuropathol. 2018 Aug;136(2):255-271. doi: 10.1007/s00401-018-1854-7. Epub 2018 May 5. Erratum in: Acta Neuropathol. 2018 Sep;136(3):505.

PMID:
29730775
28.

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade.

Klepsch V, Hermann-Kleiter N, Do-Dinh P, Jakic B, Offermann A, Efremova M, Sopper S, Rieder D, Krogsdam A, Gamerith G, Perner S, Tzankov A, Trajanoski Z, Wolf D, Baier G.

Nat Commun. 2018 Apr 18;9(1):1538. doi: 10.1038/s41467-018-04004-2.

29.

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.

George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, Maas L, Müller C, Dahmen I, Delhomme TM, Ardin M, Leblay N, Byrnes G, Sun R, De Reynies A, McLeer-Florin A, Bosco G, Malchers F, Menon R, Altmüller J, Becker C, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soloway MG, Wilkerson MD, Cun Y, McKay JD, Moro-Sibilot D, Brambilla CG, Lantuejoul S, Lemaitre N, Soltermann A, Weder W, Tischler V, Brustugun OT, Lund-Iversen M, Helland Å, Solberg S, Ansén S, Wright G, Solomon B, Roz L, Pastorino U, Petersen I, Clement JH, Sänger J, Wolf J, Vingron M, Zander T, Perner S, Travis WD, Haas SA, Olivier M, Foll M, Büttner R, Hayes DN, Brambilla E, Fernandez-Cuesta L, Thomas RK.

Nat Commun. 2018 Mar 13;9(1):1048. doi: 10.1038/s41467-018-03099-x.

30.

In silico analysis of anti-leukemia immune response and immune evasion in acute myeloid leukemia.

Krupar R, Schreiber C, Offermann A, Lengerke C, Sikora AG, Thorns C, Perner S.

Leuk Lymphoma. 2018 Oct;59(10):2493-2496. doi: 10.1080/10428194.2018.1434883. Epub 2018 Feb 12. No abstract available.

PMID:
29431550
31.

Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma.

Heinemann FG, Tolkach Y, Deng M, Schmidt D, Perner S, Kristiansen G, Müller SC, Ellinger J.

Clin Epigenetics. 2018 Jan 23;10:11. doi: 10.1186/s13148-018-0444-9. eCollection 2018.

32.

Epigenetic modifications of the VGF gene in human non-small cell lung cancer tissues pave the way towards enhanced expression.

Marwitz S, Heinbockel L, Scheufele S, Nitschkowski D, Kugler C, Perner S, Reck M, Ammerpohl O, Goldmann T.

Clin Epigenetics. 2017 Nov 28;9:123. doi: 10.1186/s13148-017-0423-6. eCollection 2017.

33.

Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.

Chen X, Bernemann C, Tolkach Y, Heller M, Nientiedt C, Falkenstein M, Herpel E, Jenzer M, Grüllich C, Jäger D, Sültmann H, Duensing A, Perner S, Cronauer MV, Stephan C, Debus J, Schrader AJ, Kristiansen G, Hohenfellner M, Duensing S.

Urol Oncol. 2018 Apr;36(4):161.e19-161.e30. doi: 10.1016/j.urolonc.2017.11.001. Epub 2017 Dec 1.

PMID:
29198908
34.

Effect of Antigen Retrieval Methods on Nonspecific Binding of Antibody-Metal Nanoparticle Conjugates on Formalin-Fixed Paraffin-Embedded Tissue.

Zhang Y, Wang XP, Perner S, Bankfalvi A, Schlücker S.

Anal Chem. 2018 Jan 2;90(1):760-768. doi: 10.1021/acs.analchem.7b03144. Epub 2017 Dec 11.

PMID:
29148719
35.

[Inhibitors of the androgen receptor N‑terminal domain : Therapies targeting the Achilles' heel of various androgen receptor molecules in advanced prostate cancer].

Hupe MC, Offermann A, Perabo F, Chandhasin C, Perner S, Merseburger AS, Cronauer MV.

Urologe A. 2018 Feb;57(2):148-154. doi: 10.1007/s00120-017-0541-y. Review. German.

PMID:
29147733
36.

Immunometabolic Determinants of Chemoradiotherapy Response and Survival in Head and Neck Squamous Cell Carcinoma.

Krupar R, Hautmann MG, Pathak RR, Varier I, McLaren C, Gaag D, Hellerbrand C, Evert M, Laban S, Idel C, Sandulache V, Perner S, Bosserhoff AK, Sikora AG.

Am J Pathol. 2018 Jan;188(1):72-83. doi: 10.1016/j.ajpath.2017.09.013. Epub 2017 Oct 27.

PMID:
29107073
37.

Mammary analogue secretory carcinoma of salivary glands: diagnostic pitfall with distinct immunohistochemical profile and molecular features.

Bissinger O, Götz C, Kolk A, Bier HA, Agaimy A, Frenzel H, Perner S, Ribbat-Idel J, Wolff KD, Weichert W, Mogler C.

Rare Tumors. 2017 Oct 3;9(3):7162. doi: 10.4081/rt.2017.7162. eCollection 2017 Oct 3.

38.

Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups.

Offermann A, Hohensteiner S, Kuempers C, Ribbat-Idel J, Schneider F, Becker F, Hupe MC, Duensing S, Merseburger AS, Kirfel J, Reischl M, Lubczyk V, Kuefer R, Perner S.

Front Med (Lausanne). 2017 Sep 29;4:157. doi: 10.3389/fmed.2017.00157. eCollection 2017.

39.

IL-4/5 signalling plays an important role during Litomosoides sigmodontis infection, influencing both immune system regulation and tissue pathology in the thoracic cavity.

Ritter M, Tamadaho RS, Feid J, Vogel W, Wiszniewsky K, Perner S, Hoerauf A, Layland LE.

Int J Parasitol. 2017 Dec;47(14):951-960. doi: 10.1016/j.ijpara.2017.06.009. Epub 2017 Aug 30.

40.

Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer.

Schecher S, Walter B, Falkenstein M, Macher-Goeppinger S, Stenzel P, Krümpelmann K, Hadaschik B, Perner S, Kristiansen G, Duensing S, Roth W, Tagscherer KE.

Int J Cancer. 2017 Oct 15;141(8):1643-1653. doi: 10.1002/ijc.30864. Epub 2017 Jul 12.

41.

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression.

Marwitz S, Scheufele S, Perner S, Reck M, Ammerpohl O, Goldmann T.

Clin Epigenetics. 2017 May 11;9:51. doi: 10.1186/s13148-017-0354-2. eCollection 2017.

42.

Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression.

Klümper N, Syring I, Vogel W, Schmidt D, Müller SC, Ellinger J, Shaikhibrahim Z, Brägelmann J, Perner S.

Front Med (Lausanne). 2017 Mar 17;4:30. doi: 10.3389/fmed.2017.00030. eCollection 2017.

43.

ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma.

Schmitt A, Knittel G, Welcker D, Yang TP, George J, Nowak M, Leeser U, Büttner R, Perner S, Peifer M, Reinhardt HC.

Cancer Res. 2017 Jun 1;77(11):3040-3056. doi: 10.1158/0008-5472.CAN-16-3398. Epub 2017 Mar 31.

44.

Prominent Oncogenic Roles of EVI1 in Breast Carcinoma.

Wang H, Schaefer T, Konantz M, Braun M, Varga Z, Paczulla AM, Reich S, Jacob F, Perner S, Moch H, Fehm TN, Kanz L, Schulze-Osthoff K, Lengerke C.

Cancer Res. 2017 Apr 15;77(8):2148-2160. doi: 10.1158/0008-5472.CAN-16-0593. Epub 2017 Feb 16.

45.

MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy.

Laban S, Giebel G, Klümper N, Schröck A, Doescher J, Spagnoli G, Thierauf J, Theodoraki MN, Remark R, Gnjatic S, Krupar R, Sikora AG, Litjens G, Grabe N, Kristiansen G, Bootz F, Schuler PJ, Brunner C, Brägelmann J, Hoffmann TK, Perner S.

Oncotarget. 2017 Feb 28;8(9):14719-14735. doi: 10.18632/oncotarget.14830.

46.

Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy.

von Klot CA, Kuczyk MA, Boeker A, Reuter C, Imkamp F, Herrmann TR, Tezval H, Kramer MW, Perner S, Merseburger AS.

Oncol Lett. 2017 Jan;13(1):22-28. doi: 10.3892/ol.2016.5392. Epub 2016 Nov 17.

47.

FirebrowseR: an R client to the Broad Institute's Firehose Pipeline.

Deng M, Brägelmann J, Kryukov I, Saraiva-Agostinho N, Perner S.

Database (Oxford). 2017 Jan 6;2017. doi: 10.1093/database/baw160. Print 2017.

49.

Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.

von Mässenhausen A, Brägelmann J, Billig H, Thewes B, Queisser A, Vogel W, Kristiansen G, Schröck A, Bootz F, Brossart P, Kirfel J, Perner S.

Int J Mol Sci. 2016 Dec 22;18(1). pii: E7. doi: 10.3390/ijms18010007.

50.

MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.

Offermann A, Vlasic I, Syring I, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Hagedorn S, Behrends J, Nowak M, Merseburger A, Bubendorf L, Kirfel J, Duensing S, Shaikhibrahim Z, Perner S.

Oncotarget. 2017 Jan 31;8(5):7964-7976. doi: 10.18632/oncotarget.13860.

Supplemental Content

Loading ...
Support Center